DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2008/0063698 A1 Hartwig (43) Pub

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2008/0063698 A1 Hartwig (43) Pub US 2008 OO63698A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0063698 A1 Hartwig (43) Pub. Date: Mar. 13, 2008 (54) CRYSTALLIZATION INHIBITION OF DRUGS now abandoned, which is a continuation of applica IN TRANSIDERMAL DRUG DELIVERY tion No. 10/010,342, filed on Dec. 5, 2001, now SYSTEMIS AND METHODS OF USE abandoned. (75) Inventor: Rod Lawson Hartwig, Plantation, FL (60) Provisional application No. 60/251.294, filed on Dec. (US) 5, 2000. Correspondence Address: Publication Classification Noven Pharmaceuticals, Inc. Jay G. Kolman, Esq. (51) Int. Cl. 11960 S.W. 144 Street A6II 3/56 (2006.01) A6F 3/00 (2006.01) Miami, FL 33186 (US) A6IP 43/00 (2006.01) (73) Assignee: NOVEN PHARMACEUTICALS, A6F 3/02 (2006.01) INC. (52) U.S. Cl. ........................... 424/448; 424/449; 514/170 (57) ABSTRACT Appl. No.: 11/897,189 (21) The invention relates to compositions and methods for (22) Filed: Aug. 29, 2007 making a transdermal drug delivery system capable of achieving substantially zero-order kinetics for delivery of Related U.S. Application Data the active agent over a period of time in excess of 24 hours and at least 72 hours, comprising a pharmaceutically accept (63) Continuation of application No. 10/751,152, filed on able active agent carrier and a rosin ester which provides a Jan. 2, 2004, now abandoned, which is a continuation crystal inhibiting and drug stabilizing effect on the active of application No. 10/353,624, filed on Jan. 29, 2003, agents incorporated therein. 13 2 2 Patent Application Publication Mar. 13, 2008 Sheet 2 of 4 US 2008/0063698 A1 s 5 3 O (zuo/6n) uoneeued empernuno Patent Application Publication Mar. 13, 2008 Sheet 3 of 4 US 2008/0063698 A1 at O N N O vd X O - L t O cC - Hv E. O L 2 a X- cywd > y g ar. n n CO () (d an c. s. 5. r E E E cus ( cus X X X U o s 8 o (Zuo/6n) uola eeuied empaenung Patent Application Publication Mar. 13, 2008 Sheet 4 of 4 US 2008/0063698 A1 d Cl E X L s s US 2008/0063698 A1 Mar. 13, 2008 CRYSTALLIZATION INHIBITION OF DRUGS IN system can provide a continuous and controlled release of TRANSIDERMAL DRUG DELVERY SYSTEMS the active agent over a prolonged period of time so that the AND METHODS OF USE resulting blood levels remain constant. CROSS-REFERENCE TO RELATED 0008. It has been shown that the degree of saturation and APPLICATION solubility of the active agent in the carrier composition are determining factors in controlling delivery of the active 0001. This application is based on and claims the benefit agent from the transdermal system. Since only solubilized of Provisional Application 60/251.294 filed Dec. 5, 2000, active agent is available for delivery out of the transdermal which is incorporated in its entirety herein by reference. system, the carrier composition must not promote crystal growth or formation, especially during storage of the system BACKGROUND OF THE INVENTION prior to use. Generally, active agents have been found to be 0002 This invention relates generally to transdermal readily soluble in acrylic polymers. However, in order to drug delivery systems, and more particularly to pressure deliver a therapeutically effective amount to the systems sensitive adhesive compositions, that incorporate rosin user, and to also achieve the desired adhesive strength esters to inhibit crystal formation of the active agent in the required for topical application in a matrix-type system, composition during storage. additional polymers and ingredients are often added to the carrier composition (for example, incorporating a rubber, 0003. The use of transdermal drug delivery systems as a polysiloxane or polyvinylpyrrolidone polymer). Such addi means to topically administer an active agent is well known. tional polymers and ingredients can affect the recrystalliza Such systems incorporate the active agent into a carrier tion of the active agent in the carrier composition. The composition, such as a polymeric and/or pressure-sensitive tendency for crystal formation or growth is known, for adhesive composition, from which the active agent is deliv example, in the case of high melting point hydrophobic ered through the skin or mucosa of the user. drugs, such as hormones and steroidal active agents, which 0004. In general, transdermal drug delivery systems are tend to be poorly soluble or insoluble in pressure-sensitive either reservoir-type or matrix-type. Both types of systems adhesive carrier compositions because they form strong include a backing layer that forms the protective outer crystal bonds. surface of the finished transdermal device and which is 0009 Formulation of transdermal systems is further fre exposed to the environment during use, and a release liner quently hampered by poor solubility of certain active agents or protective layer that forms the inner surface and which in the carrier composition, which in turn also severely limits covers the adhesive means for affixing the device to the skin its therapeutic application. This formulating aspect is par or mucosa of a user. The release liner or protective layer is ticularly difficult in matrix-type systems because the carrier removed prior to application, exposing the adhesive means, composition has to be optimized not only to incorporate and which is typically a pressure-sensitive adhesive. The active administer the desired active agents, but also to obtain agent is located between the release liner and backing layer, Sufficient wear properties (means of attachment to the user) usually solubilized or dispersed in a solvent or carrier for the adhesive carrier. While using low concentrations in composition. order to incorporate the active agent into the carrier may not 0005. In a reservoir-type device, the active agent, typi deleteriously affect the carrier's adhesive properties, low cally in fluid or gel form, is isolated from the adhesive means active agent concentration can result in difficulties in achiev used to affix the device to the user. Traditionally, a reservoir ing an acceptable delivery rate. Poor or inadequate solubility system referred to a device having a pocket or “reservoir of the active agent further gives rise to crystal formation or which served to hold the active agent and which was formed growth. in or by the backing layer itself. A peripheral adhesive layer 0010 Generally, concentrations of the active agent sub was then used to affix the device to the user. While such stantially at or near the Saturation solubility, and even devices are still in use today, the term reservoir has become Supersaturated (i.e., an amount of active agent at a concen known as a device which employs one or more permeable tration greater than the solubility of the active agent in the layers, such as rate controlling membranes and drug perme carrier composition at room temperature) are sought in order able adhesives layers, laminated over the reservoir (which is to increase or maximize delivery rates. Such systems are typically nothing more than another layer containing the also desirable because they provide the ability to potentially drug in a carrier composition), in order to more effectively achieve continuous administration of the active drug in control the delivery rate of the active agent and attachment therapeutically effective amounts for prolonged periods of of the device to the user. time, such as greater than 24 hours, and even up to 7 days 0006. A matrix-type device generally comprises the or more. In these systems, however, the active agent can active agent solubilized or dispersed in an adhesive carrier more easily recrystallize, especially during storage. Crystal composition, typically a pressure-sensitive adhesive or bio lization may occur after a few weeks or months of storage. adhesive, which functions as both the drug carrier and the This gives rise to stability problems. adhesive means of applying the system to the skin or 0011 Active agent that is present in crystalline form mucosa. Such devices are described, for example, in U.S. cannot be delivered through skin or mucosa. Inadequate Pat. Nos. 4,994,267, 5,446,070, 5,474,783 and 5,656,286, all delivery of the active agent in turn leads to blood levels of which are assigned to Noven Pharmaceuticals, Inc., falling below that which are therapeutically effective. Some Miami, Fla. transdermal systems rely upon both solubilized and crystal 0007. A particular advantage over other forms of drug line forms of active agent to achieve the desired drug loading delivery, Such as oral administration, is that the transdermal in the carrier composition. Although the drug crystals in US 2008/0063698 A1 Mar. 13, 2008 Such systems are intended to dissolve later, for example after recrystallization of the active agent after a few weeks or application, such a process is unpredictable and interferes months of storage, and deliver the same at a controlled and with achieving a controlled delivery rate, especially a Zero predictable release rate. order kinetic delivery rate. 0019. It is still another object of this invention to provide 0012 Failure to control crystal formation and growth can a method for increasing the solubilizing and stabilizing of further interfere with the physical properties of the trans active agents in transdermal delivery systems. dermal system. The presence of crystals, particularly in large amounts, can interfere with the carrier composition’s adhe 0020. It is additionally an object of this invention to sive properties in matrix-type transdermal systems. Further provide a method for making a transdermal drug delivery more, Surface crystals can come into direct contact with the system that achieves a Substantially Zero-order kinetic rate skin or mucosa and promote irritation. The presence of drug of drug delivery for a prolonged period of time without crystals is therefore generally undesirable.
Load more

Recommended publications
  • Analysis of Metals in Surface Water Samples
    ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Annex I Analysis of metals in surface water samples Environmental Institute, s.r.o., Okružná 784/42, 972 41 Koš, Slovakia October 2020 EUWI+, Investigative monitoring of the Dnieper River Basin, October 2020 ENVIRONMENTAL INSTITUTE, s.r.o., Okružná 784/42, 972 41 Koš Surface water samples Cd (ug/L) Pb (ug/L) Hg (ug/L) Ni (ug/L) As (ug/L) Cr (ug/L) Cu (ug/L) Zn (ug/L) Metals – limit values 0.15** 1.2** 0.07*** 4** 24* 9.0* 1.6* 9.6* Table 1: Results of analyses of Sampling point 1 filtered <LOQ <LOQ <LOQ <LOQ 3.38 <LOQ 1.15 4.0 metals in surface water samples. Sampling point 2 filtered 0.547 <LOQ <LOQ 1.845 <LOQ 0.666 1.94 26.5 The values represent dissolved Sampling point 3 filtered <LOQ <LOQ <LOQ <LOQ 1.99 <LOQ 0.89 4.1 concentrations (after filtration of Sampling point 4 filtered <LOQ <LOQ <LOQ 1.33 <LOQ <LOQ 4.21 9.2 the samples). Numbers Sampling point 5 filtered 2.66 <LOQ <LOQ <LOQ <LOQ 2.35 9.39 20.6 highlighted in orange colour Sampling point 6 filtered <LOQ <LOQ <LOQ <LOQ 2.62 <LOQ 4.95 6.9 indicate exceedance of the Sampling point 7 filtered 0.345 <LOQ <LOQ <LOQ <LOQ 0.777 6.06 38.4 toxicity threshold values. Sampling point 8 filtered <LOQ <LOQ <LOQ <LOQ 2.65 <LOQ 1.03 61.7 Sampling point 9 filtered 0.129 <LOQ <LOQ <LOQ 2.29 0.85 5.36 16.4 Sampling point 10 filtered <LOQ <LOQ <LOQ 1.772 <LOQ <LOQ <LOQ 7.9 Sampling point 11 filtered 0.292 <LOQ <LOQ <LOQ <LOQ 1.31 0.82 11.9 Sampling point 12 filtered 0.328 <LOQ <LOQ <LOQ <LOQ 3.89 1.34 2.6 Sampling point 13 filtered <LOQ
    [Show full text]
  • Anabolic-Androgenic Steroids in Horses: Natural Presence and Underlying Biomechanisms
    ANABOLIC-ANDROGENIC STEROIDS IN HORSES: NATURAL PRESENCE AND UNDERLYING BIOMECHANISMS Anneleen Decloedt Dissertation submitted in the fulfilment of the requirements for the degree of Doctor of philosophy (PhD) in Veterinary Sciences, Faculty of Veterinary Medicine, Ghent University PROMOTER Prof. dr. ir. Lynn Vanhaecke Ghent University, Faculty of Veterinary Medicine Department of Veterinary Public Health and Food Safety Laboratory of Chemical Analysis MEMBERS OF THE READING COMMITTEE Prof. dr. James Scarth HFL Sport Science, Cambridgeshire, United-Kingdom Prof. dr. Peter Van Eenoo Ghent University, DoCoLab, Zwijnaarde, Belgium Prof. dr. Ann Van Soom Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium MEMBERS OF THE EXAMINATION COMMITTEE Dr. Ludovic Bailly-Chouriberry Laboratoires des Courses Hippiques, Verrières-le-Buisson, France Dr. Leen Van Ginkel Wageningen University, RIKILT, Wageningen, The Netherlands Prof. dr. Myriam Hesta Ghent University, Faculty of Veterinary Medicine, Merelbeke, Belgium This work was funded by the Fédération Nationale des Courses Françaises (via the Laboratoire des Courses Hippiques) and executed at the Laboratory of Chemical Analysis (Faculty of Veterinary Medicine, Ghent University, Merelbeke). The author and the promoter give the authorisation to consult and to copy parts of this work for personal use only. Every other use is subject to the copyright laws. Permission to reproduce any material contained in this work should be obtained from the author. “The universe is full of magic, Just patiently waiting for our wits to grow sharper” TABLE OF CONTENTS TABLE OF CONTENTS Chapter I – General Introduction 1 1. Steroids 3 1.1 Chemical structure 1.2 (Steroid) hormones and their role in the endocrine system 1.3 Biosynthesis of steroid hormones 1.4 Anabolic-androgenic steroids (AAS) 1.5 Synthesis and absorption of the steroid precursor cholesterol 2.
    [Show full text]
  • Quick Determination of 105 Doping in Animal Derived Food By
    QTRAP®质谱系统对动物源食品中105种兴奋剂的快速分析 检测 Quick Determination of 105 Doping in Animal – derived Food by QTRAP® System 杨总1，陈丹2，程海燕1，李立军1，郭立海1 Yang Zong1，Chen Dan2，Cheng Haiyan1，Li Lijun1，Guo Lihai1 1 SCIEX亚太应用支持中心，上海； 2 湖北省武汉食品化妆品检验所 1 SCIEX Asia Pacific Application Support Center, Shanghai, China; 2 Wuhan Institute for Food and Cosmetic Control, Hubei Province, China; Keywords：doping；SCIEX QTRAP® 4500 系统； LC-MS/ MS；quantitative analysis 引言 在现代畜牧养殖业中，一些不法分子长期使用各种饲料添加 剂和人工合成激素类化合物，造成动物源食品中的药物残留，最 终成为食源性兴奋剂的来源[1]。运动员食用含有某些药物残留的食 物，可导致其兴奋剂检测呈阳性。国家反兴奋剂中心和世界反兴 奋剂机构（WADA）等组织机构明确规定了兴奋剂的违禁药物的种 SCIEX ExionLC™液相和SCIEX QTRAP® 4500质谱系统 类，主要包含了β-受体激动剂、固醇类激素、糖皮质激素、利尿 剂、玉米赤霉醇类等等。总体而言，兴奋剂的作用主要是对身体或 者中枢神经系统起到选择性的作用，能促进肌肉组织快速增长、增 4. 建立好了105种兴奋剂EPI二级谱库，软件自动进行匹配二级质 强机体活力和敏捷度，还可使运动员疲劳减轻，自信心增强，注意 谱图，保证筛查结果准确可靠； 力集中[2]。因此在体育赛事过程中，为了保证赛事结果的公平、公 正，在运动员食品安全保障过程中，必须对食品中兴奋剂进行严格 5. 方法现成，省去开发方法的时间，提高了工作效率； 的监控。本文针对动物源食品中的常见105种兴奋剂，建立了采用 QTRAP®系统快速筛查和定量方法，该方法完全满足在体育赛事过 1. 实验方法 程中对兴奋剂监管的分析要求。 1.1 液相色谱条件 该方案的特点和优势 色谱柱：Phenomenex Kinetex 2.6µm F5 100 Å 150×3 µm 流动相：水相（水中含有5 mM乙酸铵和0.01%甲酸），有机 1. 方法覆盖面广，包含了常见五大类β-受体激动剂、固醇类激 相为乙腈，梯度洗脱 素、糖皮质激素、利尿剂、玉米赤霉醇类兴奋剂，共105种； 1.2 质谱条件 2. 本实验详细优化了前处理过程，考察了化合物的稳定性； 扫描模式：MRM-IDA-EPI，正负离子同时扫描，MRM离子对见 3. 实验采用MRM-IDA-EPI扫描实现一针进样同时定量和定性分 表1。 析，快速灵敏，满足国内外标准品的要求； RUO-MKT-02-9756-ZH-A p 1 离子源：ESI源；离子源参数：喷雾电压（IS）：5500V（+） 2. 结果与讨论 /-4500V（-）；离子源温度：600℃；气帘气（CUR）：35psi；碰 2.1 前处理过程的优化 撞气（CAD）：Medium；雾化气（GS1）：55psi；辅助雾化气 （GS2）：60psi 本实验详细优化了前处理过程，实验结果表明在动物源食品 中酸化乙腈的提取效率最高，绝大部分化合物回收率在70%以上 1.3 样品前处理过程 （见图1、图2、图3）。由于基质的复杂性，实验比较了5种不同 称取5g样品于50 mL离心管 → 加入10 mL乙酸铵缓冲溶液混 的SPE柱的净化效率，由图4可以看出，PRIME HLB 净化效果最优 异，回收率较高。 匀 → 加入β-葡萄糖醛甙酶进行酶解 → 加入酸化乙腈进行提取， 震荡混匀后加入NaCl和Mg2SO4 → 萃取之后高速离心取上清液采用 PRIME HLB进行净化 → 吹干后复溶上机测试。 100 80 60 40 20 0 酸化叔丁基甲醚 酸化乙腈 碱化乙腈 图1.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Order in Council 1243/1995
    PROVINCE OF BRITISH COLUMBIA ORDER OF THE LIEUTENANT GOVERNOR IN COUNCIL Order in Council No. 12 4 3 , Approved and Ordered OCT 121995 Lieutenant Governor Executive Council Chambers, Victoria On the recommendation of the undersigned, the Lieutenant Governor, by and with the advice and consent of the Executive Council, orders that Order in Council 1039 made August 17, 1995, is rescinded. 2. The Drug Schedules made by regulation of the Council of the College of Pharmacists of British Columbia, as set out in the attached resolution dated September 6, 1995, are hereby approved. (----, c" g/J1"----c- 4- Minister of Heal fandand Minister Responsible for Seniors Presidin Member of the Executive Council (This pan is for adnwustratlye purposes only and is not part of the Order) Authority under which Order Is made: Act and section:- Pharmacists, Pharmacy Operations and Drug Scheduling Act, section 59(2)(1), 62 Other (specify): - Uppodukoic1enact N6145; Resolution of the Council of the College of Pharmacists of British Columbia ("the Council"), made by teleconference at Vancouver, British Columbia, the 6th day of September 1995. RESOLVED THAT: In accordance with the authority established in Section 62 of the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia, S.B.C. Chapter 62, the Council makes the Drug Schedules by regulation as set out in the attached schedule, subject to the approval of the Lieutenant Governor in Council. Certified a true copy Linda J. Lytle, Phr.) Registrar DRUG SCHEDULES to the Pharmacists, Pharmacy Operations and Drug Scheduling Act of British Columbia The Drug Schedules have been printed in an alphabetical format to simplify the process of locating each individual drug entry and determining its status in British Columbia.
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2006) – Supplement 1 (Rev. 1) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABACAVIR 136470-78-5 ACEXAMIC ACID 57-08-9 ABAFUNGIN 129639-79-8 ACICLOVIR 59277-89-3 ABAMECTIN 65195-55-3 ACIFRAN 72420-38-3 ABANOQUIL 90402-40-7 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABCIXIMAB 143653-53-6 ACITEMATE 101197-99-3 ABECARNIL 111841-85-1 ACITRETIN 55079-83-9 ABIRATERONE 154229-19-3 ACIVICIN 42228-92-2 ABITESARTAN 137882-98-5 ACLANTATE 39633-62-0 ABLUKAST 96566-25-5 ACLARUBICIN 57576-44-0 ABUNIDAZOLE 91017-58-2 ACLATONIUM NAPADISILATE 55077-30-0 ACADESINE 2627-69-2 ACODAZOLE 79152-85-5 ACAMPROSATE 77337-76-9 ACONIAZIDE 13410-86-1 ACAPRAZINE 55485-20-6 ACOXATRINE 748-44-7 ACARBOSE 56180-94-0 ACREOZAST 123548-56-1 ACEBROCHOL 514-50-1 ACRIDOREX 47487-22-9 ACEBURIC
    [Show full text]
  • Pharmaceutical Appendix to the Tariff Schedule 2
    Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2007) (Rev. 2) Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. ABACAVIR 136470-78-5 ACIDUM LIDADRONICUM 63132-38-7 ABAFUNGIN 129639-79-8 ACIDUM SALCAPROZICUM 183990-46-7 ABAMECTIN 65195-55-3 ACIDUM SALCLOBUZICUM 387825-03-8 ABANOQUIL 90402-40-7 ACIFRAN 72420-38-3 ABAPERIDONUM 183849-43-6 ACIPIMOX 51037-30-0 ABARELIX 183552-38-7 ACITAZANOLAST 114607-46-4 ABATACEPTUM 332348-12-6 ACITEMATE 101197-99-3 ABCIXIMAB 143653-53-6 ACITRETIN 55079-83-9 ABECARNIL 111841-85-1 ACIVICIN 42228-92-2 ABETIMUSUM 167362-48-3 ACLANTATE 39633-62-0 ABIRATERONE 154229-19-3 ACLARUBICIN 57576-44-0 ABITESARTAN 137882-98-5 ACLATONIUM NAPADISILATE 55077-30-0 ABLUKAST 96566-25-5 ACODAZOLE 79152-85-5 ABRINEURINUM 178535-93-8 ACOLBIFENUM 182167-02-8 ABUNIDAZOLE 91017-58-2 ACONIAZIDE 13410-86-1 ACADESINE 2627-69-2 ACOTIAMIDUM 185106-16-5 ACAMPROSATE 77337-76-9
    [Show full text]
  • Control Be Implemented. the First Large-Scale Systematic Olympic Games
    Br J Sports Med: first published as 10.1136/bjsm.11.4.162 on 1 December 1977. Downloaded from 162 Brit. J. Sports Med. - Vol. 1 1, No. 4, December 1977, pp. 162-169 RADIOIMMUNOASSAY OF ANABOLIC STEROIDS: AN EVALUATION OF THREE ANTISERA FOR THE DETECTION OF ANABOLIC STEROIDS IN BIOLOGICAL FLUIDS Robert DUGAL, Ph.D., Claire DUPUIS, Ph.D. and Michel J. BERTRAND, Ph.D. Centre de Recherches en Sciences de la Sante, Institut National de la Recherche Scientifique, Centre Hospitalier Louis-H. Lafontaine, Montrdal, Quebec, Canada ABSTRACT Recently developped radioimmunoassays (RIA) for the analysis of anabolic steroids and their metabolites in biological fluids were tested for cross-reactivity with other types of steroids. Results show that the degree of desirable cross-reactivity within the two classes of orally active anabolic steroids vary widely and that the antiserum for 19-Nortestosterone (the active principle of intramuscular, preparations) has a very high degree of undesirable cross- reactivity with components of oral contraceptives. Single and multiple dose studies in human volunteers demonstrate that the detection level and degree of retrospectivity are likewise variable but that the test easily detects most anabolic steroids during treatment. At the present time, the combination of the three antisera for the assay of a sample appears to be a relatively rapid and economic method for screening large numbers of samples in situations where doping control of anabolic steroids is required. The importance of utilizing physico-chemical means for identification of RIA potential positives is emphasized. INTRODUCTION (Sumner, 1974: Brooks et al, 1975) and identification procedures for a limited number of them have also been copyright.
    [Show full text]
  • Nomenclature of Steroids
    Pure&App/. Chern.,Vol. 61, No. 10, pp. 1783-1822,1989. Printed in Great Britain. @ 1989 IUPAC INTERNATIONAL UNION OF PURE AND APPLIED CHEMISTRY and INTERNATIONAL UNION OF BIOCHEMISTRY JOINT COMMISSION ON BIOCHEMICAL NOMENCLATURE* NOMENCLATURE OF STEROIDS (Recommendations 1989) Prepared for publication by G. P. MOSS Queen Mary College, Mile End Road, London El 4NS, UK *Membership of the Commission (JCBN) during 1987-89 is as follows: Chairman: J. F. G. Vliegenthart (Netherlands); Secretary: A. Cornish-Bowden (UK); Members: J. R. Bull (RSA); M. A. Chester (Sweden); C. LiCbecq (Belgium, representing the IUB Committee of Editors of Biochemical Journals); J. Reedijk (Netherlands); P. Venetianer (Hungary); Associate Members: G. P. Moss (UK); J. C. Rigg (Netherlands). Additional contributors to the formulation of these recommendations: Nomenclature Committee of ZUB(NC-ZUB) (those additional to JCBN): H. Bielka (GDR); C. R. Cantor (USA); H. B. F. Dixon (UK); P. Karlson (FRG); K. L. Loening (USA); W. Saenger (FRG); N. Sharon (Israel); E. J. van Lenten (USA); S. F. Velick (USA); E. C. Webb (Australia). Membership of Expert Panel: P. Karlson (FRG, Convener); J. R. Bull (RSA); K. Engel (FRG); J. Fried (USA); H. W. Kircher (USA); K. L. Loening (USA); G. P. Moss (UK); G. Popjiik (USA); M. R. Uskokovic (USA). Correspondence on these recommendations should be addressed to Dr. G. P. Moss at the above address or to any member of the Commission. Republication of this report is permitted without the need for formal IUPAC permission on condition that an acknowledgement, with full reference together with IUPAC copyright symbol (01989 IUPAC), is printed.
    [Show full text]
  • Regioselective Enzymatic Acylation of Vicinal Diols of Steroids
    Tetrahedron 61 (2005) 3065–3073 Regioselective enzymatic acylation of vicinal diols of steroids M. Manuel Cruz Silva,a Sergio Rivab and M. Luisa Sa´ e Meloa,* aCentro de Estudos Farmaceˆuticos, Lab. Quı´mica Farmaceˆutica, Faculdade de Farma´cia, Universidade de Coimbra, Rua do Norte 3000-295 Coimbra, Portugal bIstituto di Chimica del Riconoscimento Molecolare, C.N.R., Via Mario Bianco 9, 20131 Milano, Italy Received 28 October 2004; revised 29 November 2004; accepted 25 January 2005 Abstract—Monoacylated derivatives of a complete set of 2,3- and 3,4-vicinal diols of steroids were prepared by regioselective lipase- catalysed transesterification reactions. The enzymes displayed different selectivities towards the vicinal diols depending on the configuration of the hydroxyl groups. q 2005 Elsevier Ltd. All rights reserved. 1. Introduction Studies on the transesterification of polyfunctionalyzed steroids have shown that hydrolases can have access to Polyhydroxylated steroids bearing vicinal diols on the substituents either on the A-ring or on the D-ring and/or on A-ring are frequently found in Nature and some of them the side-chain of steroids. Several lipases showed a have relevant biological activities. For instance, the trans- preference for C-3 hydroxyl groups,13,14 whereas the diaxial 2b,3a-di-hydroxy pattern is present in natural protease subtilisin Carlsberg catalysed the acylation of 14 sulphated sterols with antiviral1 or anti-angiogenic2 action, C-17 OH. Moreover, stereoselective resolutions of while 2a,3a-diols isolated from marine sources hold epimeric alcohols located on the steroid side-chain have 15 cytotoxic activity.3 Steroidal saponins displaying trans- been carried out by lipase PS and, more recently, by 16 diequatorial 2a,3b-vicinal diols are quite frequent as subtilisin.
    [Show full text]
  • United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug
    USOO544607OA United States Patent 19 11 Patent Number: 5,446,070 Mantelle (45) Date of Patent: "Aug. 29, 1995 54 COMPOST ONS AND METHODS FOR 4,659,714 4/1987 Watt-Smith ......................... 514/260 TOPCAL ADMNSTRATION OF 4,675,009 6/1987 Hymes .......... ... 604/304 PHARMACEUTICALLY ACTIVE AGENTS 4,695,465 9/1987 Kigasawa .............................. 424/19 4,748,022 5/1988 Busciglio. ... 424/195 75 Inventor: Juan A. Mantelle, Miami, Fla. 4,765,983 8/1988 Takayanagi. ... 424/434 4,789,667 12/1988 Makino ............ ... 514/16 73) Assignee: Nover Pharmaceuticals, Inc., Miami, 4,867,970 9/1989 Newsham et al. ... 424/435 Fla. 4,888,354 12/1989 Chang .............. ... 514/424 4,894,232 1/1990 Reul ............. ... 424/439 * Notice: The portion of the term of this patent 4,900,552 2/1990 Sanvordeker .... ... 424/422 subsequent to Aug. 10, 2010 has been 4,900,554 2/1990 Yanagibashi. ... 424/448 disclaimed. 4,937,078 6/1990 Mezei........... ... 424/450 Appl. No.: 112,330 4,940,587 7/1990 Jenkins ..... ... 424/480 21 4,981,875 l/1991 Leusner ... ... 514/774 22 Filed: Aug. 27, 1993 5,023,082 6/1991 Friedman . ... 424/426 5,234,957 8/1993 Mantelle ........................... 514/772.6 Related U.S. Application Data FOREIGN PATENT DOCUMENTS 63 Continuation-in-part of PCT/US92/01730, Feb. 27, 0002425 6/1979 European Pat. Off. 1992, which is a continuation-in-part of Ser. No. 0139127 5/1985 European Pat. Off. 813,196, Dec. 23, 1991, Pat. No. 5,234,957, which is a 0159168 10/1985 European Pat.
    [Show full text]